Actively Recruiting
Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Led by Universiti Kebangsaan Malaysia Medical Centre · Updated on 2020-07-28
140
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.
CONDITIONS
Official Title
Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Malaysian citizens who are able to give valid consent
- Patients planned for ERCP (either emergency or elective)
You will not qualify if you...
- Known hypersensitivity to Ketamine or Midazolam
- Patient refusal to participate or unable to give consent
- Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)
- Uncontrolled hypertension (BP >160/100) and tachycardia (heart rate >120)
- Acute myocardial infarction, acute coronary syndrome (<3 months)
- Tachyarrhythmia
- Pregnancy
- Intravenous drug use or substance abuse
- History of hallucination
- Child-Pugh Class C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Kebangsaan Malaysia Medical center
Bandar Tun Razak, Kuala Lumpur, Malaysia, 56000
Actively Recruiting
Research Team
M
Muhammad Hafiz Ismail, MBBS
CONTACT
I
Ian Chik, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here